

Causal inference: Learning what works

Course in Uppsala, June 8-9, 2020

Professor Miguel Hernan, Harvard University

Health Economic Forum at Uppsala University (HEFUU) invites researchers and doctoral students – both from medical and social sciences – to a course on causal inference from epidemiological and medical perspective with Professor Miguel Hernan, Harvard University. The objective of the course is to learn how to determine “what works” using data from observational and randomized studies.

Professor Hernan is a leading academic in the interplay between causal inference and machine learning. His research is focused on learning what works for the treatment and prevention of diseases like cancer, cardiovascular disease, and HIV infection. He has an interest in how to generate, analyze, and interpret data to guide health policy and clinical decisions.

The cost for the course is 2000 SEK, but is reduced to 1000 SEK for students, and covers lunch and coffee during both days. Register for the course at www.hefuu.uu.se

Course description

The course introduces students to a general framework for the assessment of comparative effectiveness and safety, with an emphasis of the use of routinely collected data in healthcare settings. The framework relies on the specification and emulation of a hypothetical randomized trial: the target trial. The course explores key challenges for causal inference and critically reviews methods proposed to overcome those challenges. The methods are presented in the context of several case studies for cancer, cardiovascular, renal, and infectious diseases.

Welcome!

Erik Grönqvist, Sophie Langenskiöld and Bertil Lindahl
on behalf of HEFUU

The Health Economic Forum at Uppsala University (www.hefuu.uu.se) is an interdisciplinary forum for researchers at Uppsala University interested in health economics.

Syllabus

Causal inference: Learning what works

Instructor: Miguel Hernán

Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health

Course objective: To learn how to determine “what works” using data from observational and randomized studies

Description: The course introduces students to a general framework for the assessment of comparative effectiveness and safety, with an emphasis of the use of routinely collected data in healthcare settings. The framework relies on the specification and emulation of a hypothetical randomized trial: the target trial. The course explores key challenges for causal inference and critically reviews methods proposed to overcome those challenges. The methods are presented in the context of several case studies for cancer, cardiovascular, renal, and infectious diseases.

Learning Objectives: After successful completion of this course, students will be able to:

1. Formulate sufficiently well-defined causal questions for comparative effectiveness research
2. Specify the protocol of the target trial
3. Design analyses of observational data that emulate the protocol of the target trial
4. Identify key assumptions for a correct emulation of the target trial
5. Decide when g-methods are required for data analysis
6. Critique observational studies and randomized trials for comparative effectiveness research

Pre-course reading: Chapters 1-3 of the book Hernán MA, Robins JM (2020). Causal Inference. Boca Raton: Chapman & Hall/CRC, forthcoming. The book can be downloaded (for free) from <http://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/>

Tentative Course Outline

Day 1

1. Introduction: Asking causal questions
Case study #1: Hormone therapy and coronary heart disease
2. Emulating the target trial
Case Study #2: Statins and mortality in cancer patients
3. Choosing time zero
Case study #3: Screening colonoscopy and colorectal cancer
4. Confounding adjustment: emulating randomization
Case study #4: Statins and coronary heart disease
5. Treatment strategies
Case study #5: Epoetin dosing and mortality in hemodialysis patients

Day 2

6. Sustained treatment strategies
7. Strategies with a grace period
Case study #4: When to start antiretroviral therapy in HIV-infected individuals
8. Instrumental variable estimation
Case study #6: Screening for colon cancer
9. Randomized trials
Case study #5: Hormone therapy and breast cancer

Further reading:

- Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *American Journal of Epidemiology* 2016; 183(8):758-764
- Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *Journal of Clinical Epidemiology* 2016; 79: 70-75
- Garcia-Albeniz X, Hsu J, Hernán MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. *European Journal of Epidemiology* 2017; 32(6): 495-500
- Hernán MA. How to estimate the effect of treatment duration on survival using observational data. *BMJ* 2018; 360:k182.